Evidence map›Paper›PMID 37071150›Full record

ArticleJournal of neurology2023

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).

Maryam Oskoui, John W Day, Nicolas Deconinck, Elena S Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie Goemans, Janbernd Kirschner and 13 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 11 countries.

Maryam OskouiDepartments of Pediatrics and Neurology and Neurosurgery, McGill University, Montreal, Canada. maryam.oskoui@mcgill.ca.ORCID http://orcid.org/0000-0003-1042-0108
John W DayDepartment of Neurology, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0002-0086-9529
Nicolas DeconinckNeuromuscular Reference Center, UZ Gent, Ghent, Belgium.ORCID http://orcid.org/0000-0003-4284-6154
Elena S MazzonePediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-7857-5600
Andres NascimentoNeuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, CIBERER-ISC III, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4952-5732
Kayoko SaitoInstitute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2632-0873
Carole VuillerotDepartment of Pediatric Physical Medicine and Rehabilitation, Hôpital Mère Enfant, CHU-Lyon, Lyon, France.ORCID http://orcid.org/0000-0003-4995-0202
Giovanni BaranelloThe Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London and Great Ormond Street Hospital Trust, London, UK.ORCID http://orcid.org/0000-0003-4871-6692
Nathalie GoemansNeuromuscular Reference Centre, Department of Paediatrics and Child Neurology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5157-7155
Janbernd KirschnerDepartment of Neuropediatrics and Muscle Disorders, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-1618-7386
Anna Kostera-PruszczykDepartment of Neurology, Medical University of Warsaw, Warsaw, Poland.ORCID http://orcid.org/0000-0002-7309-1914
Laurent ServaisI-Motion-Hôpital Armand Trousseau, Paris, France.ORCID http://orcid.org/0000-0001-9270-4061
Gergely PappPharma Development, Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Ksenija GorniPDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID http://orcid.org/0000-0002-7510-1127
Heidemarie KletzlRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-8129-2196
Carmen MartinRoche Products Ltd, Welwyn Garden City, UK.
Tammy McIverRoche Products Ltd, Welwyn Garden City, UK.
Renata S ScalcoPharma Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID http://orcid.org/0000-0002-5400-562X
Hannah StauntonRoche Products Ltd, Welwyn Garden City, UK.ORCID http://orcid.org/0000-0003-4662-6490
Wai Yin YeungRoche Products Ltd, Welwyn Garden City, UK.ORCID http://orcid.org/0000-0002-9999-1048
Paulo FontouraPDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID http://orcid.org/0000-0002-3883-257X
Eugenio MercuriPediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-9851-5365
SUNFISH Working Group
Roche (Switzerland) · CHRoche (United Kingdom) · GBCentro Clinico Nemo · ITGreat Ormond Street Hospital · GBHospital Sant Joan de Déu Barcelona · ESKU Leuven · BEMcGill University Health Centre · CAMedical University of Warsaw · PLPalo Alto University · USTokyo Women's Medical University · JPUniversité Claude Bernard Lyon 1 · FRUniversité Libre de Bruxelles · BEUniversity of Freiburg · DEUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37071150
PMCPMC10129951
OpenAlexW4366238481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.